Antibody Persistence 1–5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12–23 Months of Age

Background. Following mass vaccination campaigns in the African meningitis belt with group A meningococcal conjugate vaccine, MenAfriVac (PsA-TT), disease due to group A meningococci has nearly disappeared. Antibody persistence in healthy African toddlers was investigated. Methods. African children...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Infect Dis
Hauptverfasser: Tapia, Milagritos D., Findlow, Helen, Idoko, Olubukola T., Preziosi, Marie-Pierre, Kulkarni, Prasad S., Enwere, Godwin C., Elie, Cheryl, Parulekar, Varsha, Sow, Samba O., Haidara, Fadima Cheick, Diallo, Fatoumata, Doumbia, Moussa, Akinsola, Adebayo K., Adegbola, Richard A., Kampmann, Beate, Chaumont, Julie, Martellet, Lionel, Marchetti, Elisa, Viviani, Simonetta, Tang, Yuxiao, Plikaytis, Brian D., Marc LaForce, F., Carlone, George, Borrow, Ray
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2015
Schlagworte:
The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4639509/
https://ncbi.nlm.nih.gov/pubmed/26553683
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/civ672
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge